Stockhead’s Ashtyn Hiron sits down with AdAlta (ASX:1AD) managing director and CEO Tim Oldham to close the books on 2023 and gain a sneak peek into what’s around the corner.

Oldham says 2023 for AdAlta was undoubtedly all about the progress and substantial de-risking of the company’s lead therapeutic AD-214 which is being developed for rare fibrotic diseases.

“We are now looking at potential pharmaceutical licencing partners to progress AD-214 into Phase 2 clinical trials,” he says.

“This is an active partnering space for big pharma companies, there have been 11 deals in the last 15 months, almost one a month over the last 15 months.”

Tune in to hear what’s coming up for AdAlta in 2024.